m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03360)
Name
Canakinumab
Synonyms
Ilaris (TN)
    Click to Show/Hide
Status
Approved
TTD Drug ID
D0TD2G
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interleukin-1 beta (IL1B)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-1 beta (IL1B) is a therapeutic target for Canakinumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Canakinumab through regulating the expression of Interleukin-1 beta (IL1B). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-1 beta (IL1B) is a therapeutic target for Canakinumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Canakinumab through regulating the expression of Interleukin-1 beta (IL1B). [2], [3]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-1 beta (IL1B) is a therapeutic target for Canakinumab. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Canakinumab through regulating the expression of Interleukin-1 beta (IL1B). [1], [2]
References
Ref 1 N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-KappaB pathways. Bioengineered. 2022 May;13(5):11973-11986. doi: 10.1080/21655979.2021.1999550.
Ref 2 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. doi: 10.1038/nrd2813.
Ref 3 RNA m6A reader YTHDF1 facilitates inflammation via enhancing NLRP3 translation. Biochem Biophys Res Commun. 2022 Aug 6;616:76-81. doi: 10.1016/j.bbrc.2022.05.076. Epub 2022 May 24.